Published in Arterioscler Thromb Vasc Biol on August 06, 2009
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol (2011) 2.60
High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol (2010) 2.23
Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol (2011) 1.91
Future therapeutic directions in reverse cholesterol transport. Curr Atheroscler Rep (2010) 1.46
Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. Circulation (2011) 1.03
Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr Opin Investig Drugs (2010) 0.95
Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol (2010) 0.92
Emerging therapeutic strategies to enhance HDL function. Lipids Health Dis (2011) 0.91
Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutr Metab (Lond) (2012) 0.90
Targeting high density lipoproteins in the prevention of cardiovascular disease? Curr Cardiol Rep (2012) 0.90
Effects of the Iowa and Milano mutations on apolipoprotein A-I structure and dynamics determined by hydrogen exchange and mass spectrometry. Biochemistry (2012) 0.90
The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids. Mol Med (2012) 0.89
The Impairment of Macrophage-to-Feces Reverse Cholesterol Transport during Inflammation Does Not Depend on Serum Amyloid A. J Lipids (2013) 0.85
Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice. Biochim Biophys Acta (2011) 0.83
Tweaking the cholesterol efflux capacity of reconstituted HDL. Biochem Cell Biol (2012) 0.82
Structural basis for distinct functions of the naturally occurring Cys mutants of human apolipoprotein A-I. J Lipid Res (2013) 0.82
HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilution. Biochemistry (2011) 0.80
Alginic acid cell entrapment: a novel method for measuring in vivo macrophage cholesterol homeostasis. J Lipid Res (2014) 0.76
Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. Clin Lipidol (2010) 0.75
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 10.55
New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res (2005) 4.47
Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest (2007) 4.20
Molecular physiology of reverse cholesterol transport. J Lipid Res (1995) 3.66
Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol (2003) 2.70
Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem (2007) 2.53
The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res (2007) 2.38
The structure of apolipoprotein A-I in high density lipoproteins. J Biol Chem (2007) 2.10
Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol (2003) 1.94
Determination of lecithin: cholesterol acyltransfer in human blood plasma. Scand J Clin Lab Invest (1971) 1.94
Concern Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci U S A (2006) 1.92
Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol (2006) 1.87
Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model. J Biol Chem (2003) 1.76
High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem (2000) 1.71
What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol (2005) 1.61
ABCA1-induced cell surface binding sites for ApoA-I. Arterioscler Thromb Vasc Biol (2007) 1.52
Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol (2008) 1.50
Three-dimensional models of HDL apoA-I: implications for its assembly and function. J Lipid Res (2008) 1.47
Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J Lipid Res (2008) 1.45
Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation (2003) 1.44
Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol (2008) 1.41
The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med (2002) 1.41
Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation (2001) 1.31
Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. J Biol Chem (1983) 1.23
A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb (1994) 1.19
Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I. J Lipid Res (2009) 1.14
Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol (2007) 1.11
Measurement of cholesterol bidirectional flux between cells and lipoproteins. J Lipid Res (2005) 1.11
Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol. Influence of high density lipoprotein size and structure. J Biol Chem (2004) 1.05
Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Arterioscler Thromb Vasc Biol (2007) 1.03
Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry (2002) 1.00
Apolipoprotein A-I helix 6 negatively charged residues attenuate lecithin-cholesterol acyltransferase (LCAT) reactivity. Biochemistry (2005) 1.00
Scavenger receptor class B, type I-mediated uptake of various lipids into cells. Influence of the nature of the donor particle interaction with the receptor. J Biol Chem (2001) 0.99
Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol (1999) 0.98
Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol (2006) 0.96
Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins. Biochemistry (2005) 0.96
Activation of lecithin cholesterol acyltransferase by a disulfide-linked apolipoprotein A-I dimer. Biochem Biophys Res Commun (1997) 0.95
AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet (1985) 0.95
A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux. J Biol Chem (2006) 0.94
Concentrations of electrophoretic and size subclasses of apolipoprotein A-I-containing particles in human peripheral lymph. Arterioscler Thromb Vasc Biol (2000) 0.93
Apolipoprotein A-I and the molecular variant apoA-I(Milano): evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis (2005) 0.93
Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia (2008) 0.92
Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant. Circulation (2007) 0.90
Apolipoprotein A-IMilano/POPC complex attenuates post-ischemic ventricular dysfunction in the isolated rabbit heart. Atherosclerosis (2007) 0.87
Phospholipid liposomes acquire apolipoprotein E in atherogenic plasma and block cholesterol loading of cultured macrophages. J Clin Invest (1987) 0.86
Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. Biochemistry (1999) 0.81
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature (2010) 12.07
A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med (2003) 9.23
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One (2008) 7.16
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet (2007) 5.88
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res (2005) 4.47
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45
Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med (2009) 4.45
NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem (2004) 4.37
Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest (2007) 4.20
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med (2010) 3.73
The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res (2008) 3.71
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med (2007) 3.70
Resistin is an inflammatory marker of atherosclerosis in humans. Circulation (2005) 3.52
Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol (2002) 3.51
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med (2004) 3.49
Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation (2006) 3.49
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med (2004) 3.34
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 3.26
Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation (2005) 3.25
Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation (2003) 3.24
The metabolic syndrome: more than the sum of its parts? Circulation (2003) 3.22
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol (2010) 3.20
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet (2011) 3.07
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A (2006) 3.00
Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med (2003) 2.98
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet (2010) 2.91
COX-2-derived prostacyclin confers atheroprotection on female mice. Science (2004) 2.87
Inflammation impairs reverse cholesterol transport in vivo. Circulation (2009) 2.86
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet (2009) 2.85
Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol (2003) 2.70
Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J Lipid Res (2005) 2.61
Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem (2007) 2.53
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res (2008) 2.51
An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med (2004) 2.51
CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med (2014) 2.50
Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest (2005) 2.47
Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol (2008) 2.41
The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res (2007) 2.38
Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest (2011) 2.37
Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA (2003) 2.32
Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis (2011) 2.25
High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol (2010) 2.23
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Characterization of the lipolytic activity of endothelial lipase. J Lipid Res (2002) 2.16
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Statins and cognitive function: a systematic review. Ann Intern Med (2013) 2.10
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med (2008) 1.97
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Illuminating HDL--is it still a viable therapeutic target? N Engl J Med (2007) 1.94
Update on strategies to increase HDL quantity and function. Nat Rev Cardiol (2009) 1.94
Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation (2007) 1.93
Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol (2011) 1.91